Exosomes Diagnostic and Therapeutic Market Growth Outlook 2024 to 2034

Increasing demand for non-invasive biomarkers to catapult growth in the exosome diagnostic and therapeutic market. The market size is expected to increase from US$ 88.56 million in 2024 to US$ 211.6 million by 2034, at a 9.10% CAGR.

Attributes Key Insights
Estimated Exosomes Diagnostic and Therapeutic Market Size (2024E) US$ 88.56 million
Projected Exosomes Diagnostic and Therapeutic Market Valuation (2034F) US$ 211.6 million
Value-based CAGR (2024 to 2034) 9.10%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Emerging Trends and Opportunities in the Exosomes Diagnostic and Therapeutic Market

The healthcare sector is facing pressure to reduce the prices of healthcare services to increase their accessibility among the rising patient population. In this regard, laboratories are adopting solutions that are integrated with informatics. This helps boost productivity with the help of available resources.

Manufacturers are taking an opportunistic approach by offering such healthcare facilities with additional services and support in terms of diagnostic test products. Consequently, contributes to market growth.

Key players are also capitalizing on the growing demand for non-invasive tests to diagnose cancer. For this, they continue to maintain partnerships with academic institutes to develop novel non-invasive diagnostics.

Category-wise Exosomes Diagnostic and Therapeutic Market Analysis

Exosomes are Excessively Used for Diagnostic Purposes

Leading Application Diagnostics
Value Share (2024) 68.0%

Based on application, the exosome-based diagnostics segment acquired a massive value share of 68% in 2023. Significant use of exosomes for diagnostic purposes can be attributed to their effective delivery of specific disease cells like nucleic acids and proteins. Exosome diagnostic tests are presently being developed for several diseases like infectious diseases, cancer, and neurological disorders.

Instruments Segment to Capture a Sizeable Market Share

Leading Product Type Instruments
Value Share (2024) 25.0%

By product type, the instruments segment accounts for a prominent share of 25% in the exosomes diagnostic and therapeutic market. The segment is driven by rapid advancements in research and development activities in the healthcare sector. Growth in the count of manufacturers providing instruments for diagnostic and therapeutic is also propelling the segment expansion.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Global Exosomes Diagnostic and Therapeutic Sales Analysis by Country

Countries Forecast CAGR (2024 to 2034)
The United States 4.50%
Canada 5.0%
Germany 3.80%
China 10.0%
India 9.50%

Research Groups in the United States Make Breakthroughs in Cancer Diagnosis with Exosomes

Market players are exploiting the potential for the exosome diagnostic and therapeutic industry in the United States, which is estimated to grow at 4.5% CAGR over the forecast period. Exosomes have been receiving significant traction over the past few years due to their remarkable therapeutic possibilities.

They can be harnessed for focused delivery of therapeutic agents, like nucleic acids, proteins, and pharmaceuticals, nucleic acids, throughout biological barriers. This attribute holds a lot of potential in precision medicine applications, especially in cancer therapy.

Numerous cutting-edge technologies and the latest strategies have been developed to harness the capability of exosomes to enhance the efficiency and precision of cancer detection. These approaches can revolutionize cancer diagnostics, offering non-invasive, more precise, and early detection methods.

Liquid biopsies are one such disruptive strategy in cancer treatment, which uses non-invasive collection and investigation of exosomes from body fluids like urine, blood, and saliva.

The rapid increase in cancer patients and surging funding for cancer-related research are expected to continue supporting the exosome diagnostic and therapeutic industry in the United States.

Researchers in Canada Explore Urinary Exosomes for Disease Diagnosis

Adoption of exosomes diagnostic and therapeutic in Canada is projected to surge at a CAGR of 5% through 2034. Growth of this industry is increasing as researchers are trying to understand the connection between kidney function and disorders and urinary exosomes since exosomes carry cargo across kidney cells.

The availability, non-invasive nature, and ease of sample collection of urinary exosomes make them remarkable. Non-invasive exosomes offer a cost-effective way to uncover disease causes and therapeutic targets owing to their prognostic and diagnostic sensitivity. Additionally, non-invasive biomarkers have more patient and clinical adoption than their invasive counterparts.

Conveniently distributable and cost-effective distributable urinary indicators are clinically accessible. These factors contribute to the growth of the exosomes diagnostic and therapeutic market.

Advanced Diagnostic Assays in Germany Encourage the Exosomes Diagnostic and Therapeutic Industry

The scope of exosomes diagnostic and therapeutic in Germany is estimated to expand at a CAGR of 3.80% over the next 10 years. The industry is expected to be propelled by the increasing count of research activities with a focus on applications of exosomes to access the therapeutic effects of stem cells within the country.

Growing demand for advanced diagnostic assays as well as the increasing incidence of cancer in Germany are contributing to exosomes diagnostic and therapeutic market growth. Certain common factors that are compelling growth in the industry include advancements in healthcare systems and surging funding for research and development in Germany.

Increasing Cases of Diseases in India Draws Investors’ Interest

Investments in the Indian market are projected to rise at a CAGR of 9.5% in the following decade. Increasing cases of diseases like infectious disorders, cancer, and neurological diseases in India are raising the demand for more effective treatment and diagnostic tools offered by exosomes.

Ongoing technological advancements like proteomic analysis and high-throughput techniques are facilitating the characterization and identification of exosomes. Along with this, technological progress is helping in the development of diagnostic therapies and tools based on exosomes.

Surging investments from government agencies, private investors, and pharmaceutical firms are promoting research and growth in exosome diagnostics and therapeutics. With improving regulatory acceptance for exosome-based products, the market is set for significant expansion.

China to Observe Robust Growth Over the Next Decade as Non-invasive Testing Rises in Acceptability

Demand for exosome diagnostic and therapeutic in China is expected to rise at a CAGR of 10% over the forecast period. The market is driven by an increase in clinically researched and perceived applications of exosomes as smart nano-platforms for therapy and diagnosis in the country. Additionally, market players in China are increasing their efforts to exhibit the utility of exosomes in non-invasive testing to accelerate its adoption.

Competitive Landscape

The exosome diagnostic and therapeutic industry is experiencing a high level of competition, thanks to the growing count of companies manufacturing exosome-based products. All known companies in the market are covered below. Along with the companies, the technology that they are working on is also described. The following companies may or may not be working with any regulatory agencies, however, many of them do.

AcouSort AB

It is a Swedish firm that is introducing a revolutionary acoustofluidic technology and working on exosome-based diagnostics. The European Innovation Council (EIC) rewarded AcouSort and its project partners with a total of US$ 2.5 million to create acoustofluidic thin-film actuated chip to separate exosomes from blood.

Aethlon Medical, Inc.

It is a United States-based company that focuses on addressing the unmet requirements in the global health and biodefense industry. The firm began its tumor-derived exosome research when the medical community held a view that exosomes are cellular debris.

Fast-forward to the present, a therapeutic to attend to tumor-derived exosomes presents a significant gap in cancer care. Aethlon has shown that Hemopurifier®’s affinity mechanism can detect tumor-derived exosomes behind various forms of cancer, like ovarian, breast, and metastatic melanoma.

AGC Biologics

AGC Biologics came into a service agreement with Japan’s Jikei University in April 2023. This agreement states that AGC Biologics is going to assume a feasibility study and technology transfer for a drug to cure idiopathic pulmonary fibrosis (IPF). Specifically, the ACG scientists are going to focus on recognizing the viability of developing a sample for an exosome-based treatment.

Aruna Bio

The company is leveraging the natural abilities of neural exosomes to pass the blood-brain barrier and elevate the body’s anti-inflammatory, protective, and self-repair mechanisms for neurodegenerative disorders treatment.

Latest Developments in the Exosomes Diagnostic and Therapeutic Market

  • Thermo Fisher Scientific introduced the Thermo Scientific KingFisher Apex Purification System in April 2021. This system is a high-throughput sample purification tool that is developed for scientists who want to automate the extraction of RNA, DNA, cells, and protein from an array of sample types. The system helps enhance research productivity and propel discoveries by automating and simplifying the sample preparation workflow.
  • In February 2022, Bio-Techne Corporation made public its agreement with Thermo Fisher Scientific. Under this agreement, the latter company will be helping a Bio-Techne brand called Exosome Diagnostics to develop and commercialize the ExoTRU kidney transplant rejection test.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Coverage in the Global Exosomes Diagnostic and Therapeutic Market Research Report

  • Adjacent Study of Exosome Technologies Market, Exosome Biomarkers Market, Exosome Isolation Kits Market, Exosome Analysis Market, and Exosome Therapeutics Market
  • Market Dynamics of Exosome Isolation Kits are Mentioned

Key Players in the Exosomes Diagnostic and Therapeutic Market

  • Thermo Fisher Scientific
  • NanoSomix
  • NX Pharmagen
  • Malvern Instruments
  • Capricor Therapeutic
  • Exosome Diagnostics
  • Exiqon A/S
  • System Biosciences
  • Exosome Sciences
  • Aegle Therapeutic
  • AMS Biotechnology
  • Miltenyi Biotec
  • Codiak BioSciences Inc.
  • Lonza Group (HansaBioMed Life Sciences Ltd.)
  • AcouSort AB
  • Aethlon Medical, Inc.
  • AGC Biologics
  • Anjarium Biosciences AG
  • Aruna Bio
  • Brexogen
  • Capricor Therapeutics
  • Cells for Cells
  • Ciloa
  • ConvEyXO
  • Others

Exosomes Diagnostic and Therapeutic Market Research by Categories

By Products for Exosomes Diagnostic and Therapeutic are as follows:

  • Instruments
  • Software
  • Reagents and Kits

The Market is Bifurcated Based on Applications as:

  • Diagnostics
  • Therapeutic

Key End Users of Exosomes Diagnostic and Therapeutic are:

  • Hospitals
  • Cancer Institutes
  • Diagnostic Centers
  • Others

Different Markets for Exosomes Diagnostic and Therapeutic are:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Frequently Asked Questions

What is the Market Valuation of Exosomes Diagnostic and Therapeutic Market as of 2024?

For the year 2024, the exosomes diagnostic and therapeutic industry is estimated to be valued at US$ 88.56 million.

What is the Projected Adoption Rate of Exosomes Diagnostic and Therapeutic for the Years Between 2024 to 2034?

The adoption rate of exosomes diagnostic and therapeutic is calculated to be around 9.10% for the forecast period.

How Much Revenue this Industry is Expected to Generate by 2034?

The market revenue is expected to shoot up to US$ 211.6 million by 2034.

Which Application Segment Grabs a Hefty Share in Exosomes Diagnostic and Therapeutic?

The diagnostics segment grabs a hefty share within the exosomes diagnostic and therapeutic industry.

Which Country is Expected to Expand at a Greater Pace?

China is expected to register a significant growth rate in the exosomes diagnostic and therapeutic industry.

Which Players in the Exosomes Diagnostic and Therapeutic Industry are Influential?

Anjarium Biosciences AG, Aruna Bio, and Brexogen are influential players in the exosome diagnostic and therapeutic industry.

Table of Content
1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
    4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Component
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Component, 2019 to 2023
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component, 2024 to 2034
        5.3.1. Instruments
        5.3.2. Software
        5.3.3. Reagents & Kits
    5.4. Y-o-Y Growth Trend Analysis By Component, 2019 to 2023
    5.5. Absolute $ Opportunity Analysis By Component, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034
        6.3.1. Diagnostics
        6.3.2. Therapeutic
    6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
    6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034
        7.3.1. Hospitals
        7.3.2. Cancer Institutes
        7.3.3. Diagnostic Centres
        7.3.4. Others
    7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023
    7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Western Europe
        8.3.4. Eastern Europe
        8.3.5. South Asia and Pacific
        8.3.6. East Asia
        8.3.7. Middle East and Africa
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        9.2.1. By Country
            9.2.1.1. USA
            9.2.1.2. Canada
        9.2.2. By Component
        9.2.3. By Application
        9.2.4. By End User
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Component
        9.3.3. By Application
        9.3.4. By End User
    9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Component
        10.2.3. By Application
        10.2.4. By End User
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Component
        10.3.3. By Application
        10.3.4. By End User
    10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. UK
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Western Europe
        11.2.2. By Component
        11.2.3. By Application
        11.2.4. By End User
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Component
        11.3.3. By Application
        11.3.4. By End User
    11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        12.2.1. By Country
            12.2.1.1. Poland
            12.2.1.2. Russia
            12.2.1.3. Czech Republic
            12.2.1.4. Romania
            12.2.1.5. Rest of Eastern Europe
        12.2.2. By Component
        12.2.3. By Application
        12.2.4. By End User
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Component
        12.3.3. By Application
        12.3.4. By End User
    12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        13.2.1. By Country
            13.2.1.1. India
            13.2.1.2. Bangladesh
            13.2.1.3. Australia
            13.2.1.4. New Zealand
            13.2.1.5. Rest of South Asia and Pacific
        13.2.2. By Component
        13.2.3. By Application
        13.2.4. By End User
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Component
        13.3.3. By Application
        13.3.4. By End User
    13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. Japan
            14.2.1.3. South Korea
        14.2.2. By Component
        14.2.3. By Application
        14.2.4. By End User
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Component
        14.3.3. By Application
        14.3.4. By End User
    14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of MEA
        15.2.2. By Component
        15.2.3. By Application
        15.2.4. By End User
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Component
        15.3.3. By Application
        15.3.4. By End User
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA
        16.1.1. Market Share Analysis, 2023
            16.1.1.1. By Component
            16.1.1.2. By Application
            16.1.1.3. By End User
    16.2. Canada
        16.2.1. Market Share Analysis, 2023
            16.2.1.1. By Component
            16.2.1.2. By Application
            16.2.1.3. By End User
    16.3. Brazil
        16.3.1. Market Share Analysis, 2023
            16.3.1.1. By Component
            16.3.1.2. By Application
            16.3.1.3. By End User
    16.4. Mexico
        16.4.1. Market Share Analysis, 2023
            16.4.1.1. By Component
            16.4.1.2. By Application
            16.4.1.3. By End User
    16.5. Germany
        16.5.1. Market Share Analysis, 2023
            16.5.1.1. By Component
            16.5.1.2. By Application
            16.5.1.3. By End User
    16.6. UK
        16.6.1. Market Share Analysis, 2023
            16.6.1.1. By Component
            16.6.1.2. By Application
            16.6.1.3. By End User
    16.7. France
        16.7.1. Market Share Analysis, 2023
            16.7.1.1. By Component
            16.7.1.2. By Application
            16.7.1.3. By End User
    16.8. Spain
        16.8.1. Market Share Analysis, 2023
            16.8.1.1. By Component
            16.8.1.2. By Application
            16.8.1.3. By End User
    16.9. Italy
        16.9.1. Market Share Analysis, 2023
            16.9.1.1. By Component
            16.9.1.2. By Application
            16.9.1.3. By End User
    16.10. Poland
        16.10.1. Market Share Analysis, 2023
            16.10.1.1. By Component
            16.10.1.2. By Application
            16.10.1.3. By End User
    16.11. Russia
        16.11.1. Market Share Analysis, 2023
            16.11.1.1. By Component
            16.11.1.2. By Application
            16.11.1.3. By End User
    16.12. Czech Republic
        16.12.1. Market Share Analysis, 2023
            16.12.1.1. By Component
            16.12.1.2. By Application
            16.12.1.3. By End User
    16.13. Romania
        16.13.1. Market Share Analysis, 2023
            16.13.1.1. By Component
            16.13.1.2. By Application
            16.13.1.3. By End User
    16.14. India
        16.14.1. Market Share Analysis, 2023
            16.14.1.1. By Component
            16.14.1.2. By Application
            16.14.1.3. By End User
    16.15. Bangladesh
        16.15.1. Market Share Analysis, 2023
            16.15.1.1. By Component
            16.15.1.2. By Application
            16.15.1.3. By End User
    16.16. Australia
        16.16.1. Market Share Analysis, 2023
            16.16.1.1. By Component
            16.16.1.2. By Application
            16.16.1.3. By End User
    16.17. New Zealand
        16.17.1. Market Share Analysis, 2023
            16.17.1.1. By Component
            16.17.1.2. By Application
            16.17.1.3. By End User
    16.18. China
        16.18.1. Market Share Analysis, 2023
            16.18.1.1. By Component
            16.18.1.2. By Application
            16.18.1.3. By End User
    16.19. Japan
        16.19.1. Market Share Analysis, 2023
            16.19.1.1. By Component
            16.19.1.2. By Application
            16.19.1.3. By End User
    16.20. South Korea
        16.20.1. Market Share Analysis, 2023
            16.20.1.1. By Component
            16.20.1.2. By Application
            16.20.1.3. By End User
    16.21. GCC Countries
        16.21.1. Market Share Analysis, 2023
            16.21.1.1. By Component
            16.21.1.2. By Application
            16.21.1.3. By End User
    16.22. South Africa
        16.22.1. Market Share Analysis, 2023
            16.22.1.1. By Component
            16.22.1.2. By Application
            16.22.1.3. By End User
    16.23. Israel
        16.23.1. Market Share Analysis, 2023
            16.23.1.1. By Component
            16.23.1.2. By Application
            16.23.1.3. By End User
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Component
        17.3.3. By Application
        17.3.4. By End User
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. Thermo Fisher Scientific
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
        18.1.2. NanoSomix
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
        18.1.3. NX Pharmagen
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
        18.1.4. Malvern Instruments
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
        18.1.5. Capricor Therapeutic
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
        18.1.6. Exosome Diagnostics
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
        18.1.7. Exiqon A/S
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
        18.1.8. System Biosciences
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
        18.1.9. Exosome Sciences
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
        18.1.10. Aegle Therapeutic
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
        18.1.11. AMS Biotechnology
            18.1.11.1. Overview
            18.1.11.2. Product Portfolio
            18.1.11.3. Profitability by Market Segments
            18.1.11.4. Sales Footprint
            18.1.11.5. Strategy Overview
                18.1.11.5.1. Marketing Strategy
        18.1.12. Miltenyi Biotec
            18.1.12.1. Overview
            18.1.12.2. Product Portfolio
            18.1.12.3. Profitability by Market Segments
            18.1.12.4. Sales Footprint
            18.1.12.5. Strategy Overview
                18.1.12.5.1. Marketing Strategy
        18.1.13. Codiak BioSciences Inc.
            18.1.13.1. Overview
            18.1.13.2. Product Portfolio
            18.1.13.3. Profitability by Market Segments
            18.1.13.4. Sales Footprint
            18.1.13.5. Strategy Overview
                18.1.13.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Recommendations

Healthcare

Medical Exoskeleton Market

February 2024

REP-GB-19027

306 pages

Healthcare

Diagnostic Exosome Biomarkers Market

August 2023

REP-GB-5564

324 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Exosomes Diagnostic and Therapeutic Market

Schedule a Call